10-Q: Helius Medical Technologies Reports First Quarter 2024 Results, Secures $5.6 Million in Public Offering

Helius Medical Technologies reported a net loss of $2.5 million for the first quarter of 2024, while also securing $5.6 million in net proceeds from a public offering in May.

Summary

• Helius Medical Technologies reported a net loss of $2.5 million for the first quarter of 2024, consistent with the loss in the same period of 2023.
• The company's revenue for the quarter was $135,000, with product sales of $124,000, a slight increase from $111,000 in total revenue and $106,000 in product sales in the first quarter of 2023.
• Operating expenses decreased to $3.4 million from $3.8 million year-over-year, primarily due to reduced selling, general, and administrative expenses and research and development costs.
• The company's cash and cash equivalents stood at $3.6 million as of March 31, 2024, down from $5.2 million at the end of 2023.
• Helius completed a public offering in May 2024, raising approximately $5.6 million in net proceeds.
• The company is transitioning manufacturing of its PoNS device to Minnetronix, Inc., expected to be completed in the third quarter of 2024.
• Helius is actively pursuing Medicare reimbursement for its PoNS device, with CMS having proposed payment rates for the device and mouthpiece.
• The company is also conducting clinical trials for stroke, with enrollment expected to be completed by the end of 2024 and an FDA submission targeted for mid-to-late 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in securing funding and advancing its clinical programs, the significant losses, low cash reserves, and going concern uncertainty weigh heavily on the overall sentiment. The company is facing significant financial challenges and is reliant on future funding and reimbursement success.

Positives

• The company successfully raised $5.6 million in net proceeds through a public offering in May 2024, strengthening its financial position.
• Operating expenses decreased by $371,000 compared to the same period last year, indicating improved cost management.
• CMS has proposed payment rates for the PoNS device and mouthpiece, a positive step towards Medicare reimbursement.
• The company is making progress on its stroke program, with clinical trials underway and an FDA submission targeted for 2025.
• The transition to a new contract manufacturer is expected to be completed in the third quarter of 2024, potentially improving manufacturing efficiency.

Negatives

• The company reported a net loss of $2.5 million for the first quarter of 2024, indicating ongoing financial challenges.
• Cash and cash equivalents decreased to $3.6 million, down from $5.2 million at the end of 2023.
• The company's accumulated deficit is $162.5 million, highlighting its history of losses.
• There is substantial doubt about the company's ability to continue as a going concern within one year.
• The company is still reliant on self-pay patients for revenue, as broad insurance coverage is not yet in place.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to ongoing losses and limited cash reserves.
• The transition to a new contract manufacturer could lead to delays or disruptions in the manufacturing process.
• The company's ability to achieve profitability depends on successful commercialization of the PoNS device and securing broad insurance coverage.
• Global economic conditions, including inflation and supply chain disruptions, could adversely affect the company's business and access to capital.
• The company's stock is at risk of being delisted from the Nasdaq due to not meeting minimum stockholders' equity requirements.

Future Outlook

The company expects to continue to incur operating losses and net cash outflows until it generates sufficient revenue to support its cost structure. Helius intends to fund ongoing activities by utilizing its current cash and cash equivalents, cash received from the sale of its PoNS device, and by raising additional capital through equity or debt financings. The company is also focused on securing Medicare reimbursement and expanding commercial insurance coverage for the PoNS device.

Management Comments

• The company is focused on commercializing the PoNS device in the U.S. and securing reimbursement.
• Management is working to transition manufacturing to a new partner and advance clinical trials for stroke.
• The company is actively engaging with CMS to secure Medicare payment determinations for the PoNS device.

Industry Context

The company operates in the neurotechnology sector, focusing on non-implantable devices for neurological conditions. The pursuit of Medicare reimbursement and commercial insurance coverage is a common challenge for companies in this space. The company's focus on stroke and multiple sclerosis aligns with significant unmet needs in the neurorehabilitation market.

Comparison to Industry Standards

• Helius's revenue of $135,000 is low compared to established medical device companies, but is typical for a company in the early stages of commercialization.
• The net loss of $2.5 million is significant, but not uncommon for companies investing heavily in R&D and commercialization.
• The company's cash position of $3.6 million is relatively low, highlighting the need for additional funding.
• The company's reliance on self-pay patients is a common strategy for early-stage medical device companies before securing broad insurance coverage, similar to companies like ReWalk Robotics and Second Sight Medical Products in their early stages.
• The transition to a new contract manufacturer is a common step for companies scaling up production, similar to what companies like Inogen and Tandem Diabetes Care have done in the past.

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of further dilution and potential delisting from Nasdaq.
• Employees may be impacted by potential cost-cutting measures if the company fails to secure additional funding.
• Patients may benefit from the PoNS device if the company secures reimbursement and expands access.
• Suppliers may be affected by the company's financial challenges and potential changes in manufacturing.

Next Steps

• The company will continue to pursue Medicare reimbursement for the PoNS device.
• Helius will complete the transition of manufacturing to Minnetronix, Inc. in the third quarter of 2024.
• The company will continue enrollment in its stroke clinical trials, with an FDA submission targeted for mid-to-late 2025.
• Helius will submit a plan to Nasdaq to regain compliance with minimum stockholders' equity requirements.

Key Dates

Keywords

PoNS, neuromodulation, gait deficit, balance deficit, multiple sclerosis, stroke, Medicare, reimbursement, clinical trials, medical device